Everolimus and Itraconazole interaction

Everolimus and Itraconazole: both prescribing labels flag this combination with the strongest language, such as a contraindication, a boxed warning, or an instruction to avoid it.

Major

Do not combine without a prescriber's guidance. The label language below is the strongest FDA uses.

What the FDA labels say

From the Everolimus (Afinitor) label · effective 2026-06-01

Major

Do not administer antifungal agents, unless fungal infection has been diagnosed.

Warnings and precautionsby drug classView label on DailyMed
Major

Strong CYP3A inhibitor and P-gp inhibitor : Avoid coadministration.

Drug interactionsby drug classView label on DailyMed
Major

Effect of Other Drugs on AFINITOR/AFINITOR DISPERZ Strong or Moderate CYP3A Inhibitor and P-gp Inhibitor Avoid the coadministration of a strong CYP3A inhibitor and P-gp inhibitor [see Dosage and Administration (2.11), Clinical Pharmacology (12.3)] .

Drug interactionsby drug classView label on DailyMed
Moderate

Moderate CYP3A inhibitor and P-gp inhibitor : Reduce the dosage as recommended.

Drug interactionsby drug classView label on DailyMed

From the Itraconazole (Tolsura) label · effective 2025-04-23

Major

Co-administration with eliglustat is contraindicated in poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors.

Boxed warningby drug classView label on DailyMed
Major

…and Drug Interactions (7.1) ] Co-administration with colchicine, fesoterodine and solifenacin is contraindicated in subjects with varying degrees of renal or hepatic impairment, and Co-administration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors.

Boxed warningby drug classView label on DailyMed
Major

Co-administration with eliglustat is contraindicated in subjects that are poor or intermediate metabolizers of CYP2D6 and in subjects taking strong or moderate CYP2D6 inhibitors [see Drug Interactions (7.1) ] .

Contraindicationsby drug classView label on DailyMed
Major

Immunosuppressants Everolimus Sirolimus Temsirolimus (IV) Not recommended during and 2 weeks after TOLSURA treatment.

Drug interactionsby drug classView label on DailyMed
Major

Eliglustat CYP2D6 EMs EMs: extensive metabolizers; IMs: intermediate metabolizers, PMs: poor metabolizers. taking a strong or moderate CYP2D6 inhibitor, CYP2D6 IMs , or CYP2D6 PMs : Contraindicated during and 2 weeks after TOLSURA treatment.

Drug interactionsby drug classView label on DailyMed

Taking more than these two? Interactions stack. Check your whole list at once; it stays in your browser.

Open in the checker

Not medical advice. Interaction Checker quotes FDA label text and NIH fact sheets. Whether an interaction matters for you depends on doses, timing, kidney and liver function, and other conditions. Confirm with a pharmacist or prescriber.